The goal of this first study comparing Nano-MRI (MRI with a ferumoxtran-10 contrast agent) and 68Ga PSMA- PET/CT was to investigate a potential complementary role for these novel imaging modalities in identifying suspect lymph nodes in prostate cancer patients. Nano-MRI in a comparison with 68Ga-PSMA-...
(UroToday.com) The European Multidisciplinary Congress on Urological Cancers (EMUC) 2020 virtual meeting featured a discussion of nanoparticles in the Fragments of Imaging session by Dr. Jelle Barentsz. Dr. Barentsz notes that according to the European Association of Urology (EAU) guidelines, pelvic lymph node dissection is...
Accurate detection of lymph-node metastases in prostate cancer is an essential component of the approach to treatment. We investigated whether highly lymphotropic superparamagnetic nanoparticles, which gain access to lymph nodes by means of interstitial–lymphatic fluid transport, could be used in conjunction with high-resolution magnetic resonance...
SPL Medical BV has received approval of the German regulatory body for pharmaceutical products BfArM, to the start of a multicenter clinical trial of Ferrotran®. This is a novel contrast agent (based on Ferumoxtran-10) for use in MRI (magnetic resonance imaging), developed for the (early)...
Radboudumc has used Ferrotran (Ferumoxtran-10) from the Nijmegen company SPL Medical successfully in hundreds of patients; a new investment round for European registration of Ferrotran....
To prospectively evaluate the feasibility of magnetic resonance (MR) imaging with ferumoxtran-10 in patients with prostate cancer to depict lymph node metastases outside the routine pelvic lymph node dissection (PLND) area....
In patients with prostate cancer who are deemed to be at intermediate or high risk of having nodal metastases, invasive diagnostic pelvic lymph-node dissection (PLND) is the gold standard for the detection of nodal disease. However, a new lymph-node-specific MR-contrast agent ferumoxtran-10 can detect metastases...